Switzerland's Oculis reports wider FY25 net loss

Oculis Holding AG

03/03/2026 21:33

Overview

Switzerland-based biopharma's FY25 net loss widened YoY, with increased operating expenses

Company received FDA Breakthrough Therapy designation for Privosegtor in optic neuritis

Company on Tuesday issued 2 mln new treasury shares for potential future sales under ATM program

Outlook

Oculis expects DIAMOND Phase 3 trial results for OCS-01 in DME in Q2 2026

Company anticipates PREDICT-1 trial results for Licaminlimab in Q4 2026

Oculis plans NDA submission for OCS-01 following positive DIAMOND trial results

Result Drivers

PRIVOSEGTOR BREAKTHROUGH - FDA granted Breakthrough Therapy designation for Privosegtor in optic neuritis, supporting its potential as a neuroprotective treatment

OCS-01 TRIALS - Phase 3 DIAMOND trials with OCS-01 eye drops for DME are nearing completion, with topline results expected in Q2 2026

LICAMINLIMAB PRECISION MEDICINE - Initiated PREDICT-1 trial for Licaminlimab in dry eye disease, focusing on genotype-based precision medicine

Company press release: ID:nGNEc3PRGj

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-CHF 23.51 mln
Q4 Operating Expenses
-CHF 21.04 mln
Q4 Operating Income
CHF 411,000
Q4 Pretax Profit
-CHF 23.70 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Oculis Holding AG is $45.50, about 59% above its March 2 closing price of $28.61

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)